Eczema (Atopic Dermatitis) Clinical Trials in New Orleans

View 24 new treatments for Eczema (Atopic Dermatitis) in New Orleans, LA. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.

Ruxolitinib and Opzelura for Atopic Dermatitis

Taro Clinic, Covington + 2 more

The purpose of the study is to evaluate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib Cream) in the treatment of mild-to-moderate atopic dermatitis.Show More

Verified

Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)

Sanofi Clinic, Marrero + 2 more

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 [RIVER-AD] study).Show More

Verified

Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Lebrikizumab for Eczema

Eli Lilly Clinic, New Orleans + 1 more

This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Tralokinumab for Atopic Hand Eczema

LEO Clinic, New Orleans + 1 more

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Medical Expert
Study Director

Amlitelimab for Atopic Dermatitis (COAST 2)

Sanofi Clinic, Metairie + 2 more

This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Abrocitinib for Atopic Dermatitis/Eczema

Pfizer Clinic, New Orleans + 1 more

This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Pfizer CT.gov Call Center
Study Director

Lebrikizumab for Eczema

Eli Lilly Clinic, New Orleans + 1 more

This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Maralixibat for Itching in Liver Disease

Mirum Clinic, New Orleans + 1 more

The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Amlitelimab for Atopic Dermatitis (SHORE)

Sanofi Clinic, New Orleans + 3 more

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Amlitelimab for Atopic Dermatitis (COAST 1)

Sanofi Clinic, Covington + 1 more

This trial tests an injectable treatment called amlitelimab for people aged 12 and older with moderate to severe eczema that doesn't respond well to creams or ointments. The treatment aims to reduce skin inflammation and itching by blocking specific proteins in the immune system. The study will evaluate how effective and safe amlitelimab is.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Clinical Sciences & Operations
Study Director
Page 1 of 2

Frequently Asked Questions